DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $898,939,489 | +2.5% | 3,623,295 | -0.9% | 0.26% | +2.8% |
| Q2 2023 | $877,295,280 | -3.5% | 3,655,397 | +1.4% | 0.25% | -9.4% |
| Q1 2023 | $908,737,781 | -3.6% | 3,605,530 | +1.5% | 0.28% | -9.2% |
| Q4 2022 | $942,912,513 | +5.6% | 3,552,530 | +2.7% | 0.30% | -5.0% |
| Q3 2022 | $893,151,000 | +5.1% | 3,457,935 | +3.1% | 0.32% | +8.1% |
| Q2 2022 | $850,194,000 | -11.1% | 3,353,556 | +2.8% | 0.30% | +3.1% |
| Q1 2022 | $956,451,000 | -7.8% | 3,260,664 | +3.4% | 0.29% | -6.2% |
| Q4 2021 | $1,037,122,000 | +10.4% | 3,152,250 | +2.2% | 0.31% | -0.3% |
| Q3 2021 | $939,225,000 | +14.4% | 3,085,088 | +0.8% | 0.31% | +12.5% |
| Q2 2021 | $821,130,000 | +21.6% | 3,059,805 | +2.0% | 0.27% | +10.1% |
| Q1 2021 | $675,477,000 | +1.7% | 3,001,051 | +0.4% | 0.25% | -5.7% |
| Q4 2020 | $663,902,000 | +3.9% | 2,988,663 | +0.7% | 0.26% | -10.5% |
| Q3 2020 | $638,871,000 | +25.2% | 2,966,934 | +2.8% | 0.29% | +17.6% |
| Q2 2020 | $510,134,000 | +27.8% | 2,884,883 | +0.1% | 0.25% | +6.8% |
| Q1 2020 | $399,067,000 | -9.7% | 2,883,220 | +0.2% | 0.23% | -1.3% |
| Q4 2019 | $441,796,000 | +6.1% | 2,878,520 | -0.2% | 0.24% | -3.7% |
| Q3 2019 | $416,562,000 | +1.5% | 2,884,179 | +0.4% | 0.25% | -1.6% |
| Q2 2019 | $410,446,000 | +10.8% | 2,871,857 | +2.3% | 0.25% | +5.5% |
| Q1 2019 | $370,530,000 | +39.9% | 2,806,614 | +9.2% | 0.24% | +16.7% |
| Q4 2018 | $264,932,000 | -3.0% | 2,569,161 | +2.2% | 0.20% | +11.5% |
| Q3 2018 | $273,136,000 | +11.0% | 2,513,671 | +0.8% | 0.18% | +1.7% |
| Q2 2018 | $246,003,000 | +3.1% | 2,492,932 | +2.3% | 0.18% | -3.2% |
| Q1 2018 | $238,624,000 | +14.9% | 2,437,174 | +9.0% | 0.18% | +12.1% |
| Q4 2017 | $207,598,000 | +17.2% | 2,236,565 | +8.3% | 0.16% | +6.5% |
| Q3 2017 | $177,144,000 | +6.4% | 2,065,089 | +4.7% | 0.16% | -0.6% |
| Q2 2017 | $166,419,000 | +3.6% | 1,972,012 | +5.0% | 0.16% | -3.1% |
| Q1 2017 | $160,562,000 | +15.0% | 1,877,249 | +4.7% | 0.16% | +5.2% |
| Q4 2016 | $139,609,000 | +4.2% | 1,793,532 | +4.9% | 0.15% | -3.2% |
| Q3 2016 | $134,046,000 | -20.0% | 1,709,978 | +3.1% | 0.16% | -24.4% |
| Q2 2016 | $167,474,000 | +8.7% | 1,658,154 | +2.1% | 0.21% | +3.5% |
| Q1 2016 | $154,055,000 | +6.0% | 1,624,019 | +3.8% | 0.20% | +3.1% |
| Q4 2015 | $145,333,000 | +12.4% | 1,564,733 | +3.1% | 0.20% | +2.6% |
| Q3 2015 | $129,314,000 | -1.9% | 1,517,591 | -1.4% | 0.19% | +4.9% |
| Q2 2015 | $131,778,000 | +2.7% | 1,539,639 | +1.9% | 0.18% | +1.1% |
| Q1 2015 | $128,298,000 | +5.0% | 1,511,158 | +6.0% | 0.18% | -1.6% |
| Q4 2014 | $122,231,000 | +20.1% | 1,426,088 | +6.4% | 0.18% | +8.9% |
| Q3 2014 | $101,797,000 | -4.1% | 1,339,783 | -0.6% | 0.17% | -5.6% |
| Q2 2014 | $106,127,000 | -3.4% | 1,347,976 | -8.0% | 0.18% | -9.6% |
| Q1 2014 | $109,834,000 | -10.5% | 1,464,452 | -7.8% | 0.20% | -15.8% |
| Q4 2013 | $122,681,000 | -17.1% | 1,589,130 | -25.4% | 0.23% | -22.5% |
| Q3 2013 | $147,982,000 | +19.2% | 2,130,245 | +11.0% | 0.30% | +9.0% |
| Q2 2013 | $124,105,000 | – | 1,919,134 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |